ArticleVirologica Sinica2025
Neutralization of Crimean-Congo hemorrhagic fever pseudotyped virions with heavy chain antibodies.
Article in Virologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crimean-Congo hemorrhagic fever virus (CCHFV) is a highly pathogenic tick-borne virus that causes severe hemorrhagic fever with high mortality rates in humans. No licensed vaccines or efficacious antiviral therapies are currently available. Here, we identified seven heavy chain antibodies targeting CCHFV Gc, which consist of heavy-chain variable domain (VHH) fused to human IgG1 Fc region (VHH-Fc). These VHH-Fc antibodies exhibited neutralizing activity against both recombinant vesicular stomatitis virus (VSV)-vectored CCHFV pseudoviruses and CCHFV transcription- and entry-competent virus-like particles (tecVLPs). Among these, N025 achieved the most potent pseudovirus neutralization, while N013 showed remarkable efficacy in tecVLP systems, with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.